PMID- 26207349
OWN - NLM
STAT- MEDLINE
DCOM- 20160106
LR  - 20181113
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 121
IP  - 20
DP  - 2015 Oct 15
TI  - Long-term sustained disease control in patients with mantle cell lymphoma with or 
      without active disease after treatment with allogeneic hematopoietic cell 
      transplantation after nonmyeloablative conditioning.
PG  - 3709-16
LID - 10.1002/cncr.29498 [doi]
AB  - BACKGROUND: Previously, early results were reported for allogeneic hematopoietic 
      cell transplantation (HCT) after nonmyeloablative conditioning with 2 Gy of total 
      body irradiation with or without fludarabine and/or rituximab in 33 patients with 
      mantle cell lymphoma (MCL). METHODS: This study examined the outcomes of 70 
      patients with MCL and included extended follow-up (median, 10 years) for the 33 
      initial patients. Grafts were obtained from human leukocyte antigen 
      (HLA)-matched, related donors (47%), unrelated donors (41%), and HLA 
      antigen-mismatched donors (11%). RESULTS: The 5-year incidence of nonrelapse 
      mortality was 28%. The relapse rate was 26%. The 5-year rates of overall survival 
      (OS) and progression-free survival (PFS) were 55% and 46%, respectively. The 
      10-year rates of OS and PFS were 44% and 41%, respectively. Eighty percent of 
      surviving patients were off immunosuppression at the last follow-up. The presence 
      of relapsed or refractory disease at the time of HCT predicted a higher rate of 
      relapse (hazard ratio [HR], 2.94; P = .05). Despite this, OS rates at 5 (51% vs 
      58%) and 10 years (43% vs 45%) were comparable between those with 
      relapsed/refractory disease and those undergoing transplantation with partial or 
      complete remission. A high-risk cytomegalovirus (CMV) status was the only 
      independent predictor of worse OS (HR, 2.32; P = .02). A high-risk CMV status and 
      a low CD3 dose predicted PFS (HR, 2.22; P = .03). CONCLUSIONS: Nonmyeloablative 
      allogeneic HCT provides a long-term survival benefit for patients with relapsed 
      MCL, including those with refractory disease or multiple relapses.
CI  - (c) 2015 American Cancer Society.
FAU - Vaughn, Jennifer E
AU  - Vaughn JE
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Medical Oncology, Department of Medicine, University of Washington 
      School of Medicine, Seattle, Washington.
FAU - Sorror, Mohamed L
AU  - Sorror ML
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Medical Oncology, Department of Medicine, University of Washington 
      School of Medicine, Seattle, Washington.
FAU - Storer, Barry E
AU  - Storer BE
AD  - Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer 
      Research Center, Seattle, Washington.
AD  - Department of Biostatistics, University of Washington School of Public Health, 
      Seattle, Washington.
FAU - Chauncey, Thomas R
AU  - Chauncey TR
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Medical Oncology, Department of Medicine, University of Washington 
      School of Medicine, Seattle, Washington.
AD  - Marrow Transplant Unit, VA Puget Sound Health Care System, Seattle, Washington.
FAU - Pulsipher, Michael A
AU  - Pulsipher MA
AD  - Pediatric Blood and Marrow Transplant Program, Primary Children's Hospital, Salt 
      Lake City, Utah.
AD  - Division of Hematology/Hematological Malignancies, Huntsman Cancer Institute, 
      University of Utah School of Medicine, Salt Lake City, Utah.
FAU - Maziarz, Richard T
AU  - Maziarz RT
AD  - Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and 
      Science University, Portland, Oregon.
FAU - Maris, Michael B
AU  - Maris MB
AD  - Colorado Blood Cancer Institute, Denver, Colorado.
FAU - Hari, Parameswaran
AU  - Hari P
AD  - Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, 
      Wisconsin.
FAU - Laport, Ginna G
AU  - Laport GG
AD  - Division of Blood and Marrow Transplantation, Department of Medicine, Stanford 
      School of Medicine, Stanford, California.
FAU - Franke, Georg N
AU  - Franke GN
AD  - Division of Hematology, Oncology, and Hemostaseology, Department of Medicine, 
      University of Leipzig, Leipzig, Germany.
FAU - Agura, Edward D
AU  - Agura ED
AD  - Hematopoietic Stem Cell Program, Baylor University School of Medicine, Dallas, 
      Texas.
FAU - Langston, Amelia A
AU  - Langston AA
AD  - Division of Hematology-Oncology, Emory University School of Medicine, Atlanta, 
      Georgia.
AD  - Bone Marrow & Stem Cell Transplant Center, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Rezvani, Andrew R
AU  - Rezvani AR
AD  - Division of Blood and Marrow Transplantation, Department of Medicine, Stanford 
      School of Medicine, Stanford, California.
FAU - Storb, Rainer
AU  - Storb R
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Medical Oncology, Department of Medicine, University of Washington 
      School of Medicine, Seattle, Washington.
FAU - Sandmaier, Brenda M
AU  - Sandmaier BM
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Medical Oncology, Department of Medicine, University of Washington 
      School of Medicine, Seattle, Washington.
FAU - Maloney, David G
AU  - Maloney DG
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
AD  - Division of Medical Oncology, Department of Medicine, University of Washington 
      School of Medicine, Seattle, Washington.
LA  - eng
GR  - CA078902/CA/NCI NIH HHS/United States
GR  - T32 HL007093/HL/NHLBI NIH HHS/United States
GR  - P01 CA018029/CA/NCI NIH HHS/United States
GR  - P30 CA015704/CA/NCI NIH HHS/United States
GR  - R00 HL088021/HL/NHLBI NIH HHS/United States
GR  - CA018029/CA/NCI NIH HHS/United States
GR  - 5T32HL007093-38/HL/NHLBI NIH HHS/United States
GR  - CA15704/CA/NCI NIH HHS/United States
GR  - P01 CA078902/CA/NCI NIH HHS/United States
GR  - K99 HL088021/HL/NHLBI NIH HHS/United States
GR  - HL088021/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150724
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Adult
MH  - Aged
MH  - Drug Therapy/methods
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Lymphoma, Mantle-Cell/*mortality/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Mortality
MH  - Recurrence
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Analysis
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Whole-Body Irradiation/methods
PMC - PMC4592381
MID - NIHMS693090
OTO - NOTNLM
OT  - conditioning regimen
OT  - long-term follow-up
OT  - mantle cell lymphoma
OT  - nonmyeloablative conditioning
OT  - stem cell transplantation
COIS- AUTHOR DISCLOSURES: The authors have no conflicts of interest to report.
EDAT- 2015/07/25 06:00
MHDA- 2016/01/07 06:00
PMCR- 2016/10/15
CRDT- 2015/07/25 06:00
PHST- 2015/03/04 00:00 [received]
PHST- 2015/04/30 00:00 [revised]
PHST- 2015/05/11 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2016/01/07 06:00 [medline]
PHST- 2016/10/15 00:00 [pmc-release]
AID - 10.1002/cncr.29498 [doi]
PST - ppublish
SO  - Cancer. 2015 Oct 15;121(20):3709-16. doi: 10.1002/cncr.29498. Epub 2015 Jul 24.